A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Phase Ib: To explore the safety and preliminary efficacy of BL-M02D1 to further define RP2D
in a variety of solid tumors such as locally advanced or metastatic non-small cell lung
cancer. Phase II: To explore the efficacy of BL-M02D1 using single-agent RP2D obtained from
phase I clinical studies.